This Malpractice Insurer Beats the Odds

 | Feb 08, 2013 | 11:00 AM EST
  • Comment
  • Print Print
  • Print
Stock quotes in this article:


Writing medical malpractice insurance isn't an easy way to earn a living. But ProAssurance (PRA) is doing a pretty good job.

At any unpredictable moment, a runaway jury can hit a medical provider -- and hence its insurer -- with a big award. Doctors and hospitals feel that the premiums charged by malpractice insurers are already plenty high, and they balk at premium increases. Profit margins are hard to maintain, and the incidence of claims is hard to predict.

Despite these obstacles, ProAssurance, a malpractice insurer based in Birmingham, Ala., has shown a profit in every year for the past decade. The year just concluded looks likely to be its second best, with earnings of $4.52 a share, $0.12 behind the record total of $4.65 a share in 2011.

ProAssurance is also a debt-free company, an attribute you don't see too often these days. Of the 500 companies in the Standard & Poor's 500 index, only 21 are debt-free. (ProAssurance isn't in the S&P 500.)

On top of that, ProAssurance's stock is inexpensive. It sells for only 10x the past four quarters' earnings and only 1.2 x book value (corporate net worth per share).

Of the six analysts who publish opinions on ProAssurance, five rate it a Buy. But as far as I've noticed, no one is pounding the table for it. The one analyst who rates it a Hold is J. Paul Newsome of Sandler O'Neill -- and he has rated it a Hold since at least June 2010. Back then, the stock was $30. Now it's at $46.

What's more, the analysts' price target hardly seems aggressive. The consensus is that the stock should hit $50 by a year from now. I believe a more reasonable one-year price target would be $54, which would be up about 17% from Thursday's closing level. That figure would be 13x analysts' consensus guess about 2013 earnings, which is $4.18 a share.

The dividend yield isn't bad, a little over 2%. In my opinion, there is ample room for the dividend to be raised in the future.

Columnist Conversations

The symmetry is holding up in MCD.  Target 1 is 163.34 if we continue to hold above here!  ...
As far as TSLA is concerned, I still have a higher target above the market at the 409 area.  I stated in ...
The TLT setup discussed in my last commentary is a bust. Key support was violated and it violated the recent l...
BBY is getting smoked this mornings(weak forecast).  The stock is off 8% after opening the session with a...



News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.